Table 3.
Multivariate analysis of various factors on survivals of T3‐4 nasopharyngeal carcinoma (n = 200)
| Characteristics | 5‐year OS | 5‐year DFS | 5‐year DMFS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| T stage | ||||||
| T3 vs.T4 | 0.797 (0.177‐3.584) | .77 | 1.216 (0.282‐5.250) | .79 | 1.540 (0.195‐12.127) | .68 |
| Clinical stage | ||||||
| III vs. IVA/IVB | 2.608 (0.546‐12.467) | .23 | 1.182 (0.268‐5.210) | .82 | 0.941 (0.117‐7.574) | .96 |
| Volume of GTVnx | ||||||
| <50 cc vs. ≥50 cc | 1.408 (0.693‐2.858) | .34 | 1.570 (0.877‐2.812) | .13 | 1.234 (0.558‐2.726) | .60 |
| Volume of GTVnd | ||||||
| <15 cc vs. ≥15 cc | 2.316 (1.177‐4.560) | .02 | 2.705 (1.542‐4.747) | .001 | 3.359 (1.481‐7.619) | .004 |
Abbreviations: CI, confidence interval; DFS, disease‐free survival; DMFS, distant metastasis‐free survival; HR, hazard ratio; OS, overall survival; Volume of GTVnd, the sum volume of all involved lymph nodes; volume of GTVnx, gross tumor volume of nasopharynx.